SH-SY5Y: Human Neuroblastoma Cell Line (ATCC CRL-2266)

SK 810

SH-SY5Y: Human Neuroblastoma Cell Line (ATCC CRL-2266)

SK 810
Share
Share

Description

SH-SY5Y is a thrice-subcloned cell line derived from the SK-N-SH neuroblastoma cell line. It serves as a model for neurodegenerative disorders since the cells can be converted to various types of functional neurons by the addition of specific compounds. In addition, the SH-SY5Y cell line has been used widely in experimental neurological studies, including analysis of neuronal differentiation, metabolism, and function related to neurodegenerative processes, neurotoxicity, and neuroprotection.

Source

This cell line was derived from the SH-SY subclone of the parental SK-N-SH human neuroblastoma cell line. The parental SK-N-SH cell line was established in 1970 from metastatic cells found in the bone marrow aspirate of a four-year-old female of unknown ethnicity.

Inventors

  • June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
  • Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

Ross RA et al. (1983) Coordinate morphological and biochemical interconversion of human neuroblastoma cells. Journal of the National Cancer Institute 71: 741-748 (PubMed ID: 6137586)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

  • Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
  • Commercial License: Contact MSK’s Tangible Materials team at [email protected].
  • For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected]

Stage of Development

Ready to use

Indications